563 related articles for article (PubMed ID: 30706171)
21. The neuroprotection of cannabidiol against MPP⁺-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease.
Santos NA; Martins NM; Sisti FM; Fernandes LS; Ferreira RS; Queiroz RH; Santos AC
Toxicol In Vitro; 2015 Dec; 30(1 Pt B):231-40. PubMed ID: 26556726
[TBL] [Abstract][Full Text] [Related]
22. GPR55: A therapeutic target for Parkinson's disease?
Celorrio M; Rojo-Bustamante E; Fernández-Suárez D; Sáez E; Estella-Hermoso de Mendoza A; Müller CE; Ramírez MJ; Oyarzábal J; Franco R; Aymerich MS
Neuropharmacology; 2017 Oct; 125():319-332. PubMed ID: 28807673
[TBL] [Abstract][Full Text] [Related]
23. Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.
More SV; Choi DK
Mol Neurodegener; 2015 Apr; 10():17. PubMed ID: 25888232
[TBL] [Abstract][Full Text] [Related]
24. Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report.
Pichler EM; Kawohl W; Seifritz E; Roser P
Int J Psychiatry Med; 2019 Mar; 54(2):150-156. PubMed ID: 30058466
[TBL] [Abstract][Full Text] [Related]
25. Cannabidiol (CBD) use in psychiatric disorders: A systematic review.
Bonaccorso S; Ricciardi A; Zangani C; Chiappini S; Schifano F
Neurotoxicology; 2019 Sep; 74():282-298. PubMed ID: 31412258
[TBL] [Abstract][Full Text] [Related]
26. New pharmacological options for treating advanced Parkinson's disease.
Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
[TBL] [Abstract][Full Text] [Related]
27. A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor.
Santos de Alencar S; Crippa JAS; Brito MCM; Pimentel ÂV; Cecilio Hallak JE; Tumas V
Parkinsonism Relat Disord; 2021 Feb; 83():37-40. PubMed ID: 33465546
[TBL] [Abstract][Full Text] [Related]
28. Cannabidiol: a hope to treat non-motor symptoms of Parkinson's disease patients.
Saleem S; Anwar A
Eur Arch Psychiatry Clin Neurosci; 2020 Feb; 270(1):135. PubMed ID: 31168642
[No Abstract] [Full Text] [Related]
29. Cannabidiol in medical marijuana: Research vistas and potential opportunities.
Rong C; Lee Y; Carmona NE; Cha DS; Ragguett RM; Rosenblat JD; Mansur RB; Ho RC; McIntyre RS
Pharmacol Res; 2017 Jul; 121():213-218. PubMed ID: 28501518
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
31. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J
Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoids in Late Life Parkinson's Disease and Dementia: Biological Pathways and Clinical Challenges.
Costa AC; Joaquim HPG; Pedrazzi JFC; Pain AO; Duque G; Aprahamian I
Brain Sci; 2022 Nov; 12(12):. PubMed ID: 36552056
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders.
de Fátima Dos Santos Sampaio M; de Paiva YB; Sampaio TB; Pereira MG; Coimbra NC
Basic Clin Pharmacol Toxicol; 2024 May; 134(5):574-601. PubMed ID: 38477419
[TBL] [Abstract][Full Text] [Related]
34. Effects of intracerebral neurotrophic factor application on motor symptoms in Parkinson's disease: A systematic review and meta-analysis.
Hegarty SV; Lee DJ; O'Keeffe GW; Sullivan AM
Parkinsonism Relat Disord; 2017 May; 38():19-25. PubMed ID: 28215730
[TBL] [Abstract][Full Text] [Related]
35. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease.
de Faria SM; de Morais Fabrício D; Tumas V; Castro PC; Ponti MA; Hallak JE; Zuardi AW; Crippa JAS; Chagas MHN
J Psychopharmacol; 2020 Feb; 34(2):189-196. PubMed ID: 31909680
[TBL] [Abstract][Full Text] [Related]
36. Cannabidiol and substance use disorder: Dream or reality.
Karimi-Haghighi S; Razavi Y; Iezzi D; Scheyer AF; Manzoni O; Haghparast A
Neuropharmacology; 2022 Apr; 207():108948. PubMed ID: 35032495
[TBL] [Abstract][Full Text] [Related]
37. A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA; Bossong MG
Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
[TBL] [Abstract][Full Text] [Related]
38. The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease.
Karl T; Garner B; Cheng D
Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):142-160. PubMed ID: 27471947
[TBL] [Abstract][Full Text] [Related]
39. Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey.
Boehnke KF; Gagnier JJ; Matallana L; Williams DA
J Pain; 2021 May; 22(5):556-566. PubMed ID: 33400996
[TBL] [Abstract][Full Text] [Related]
40. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
Prediger RD
J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
